Drug Delivery System Adoption: Beyond the Formulation
Updated: Sep 3
Why Next-Gen Drug Delivery Systems Fail at Adoption (And How to Fix It)
The Formulation Breakthrough vs. The Market Reality
Pharma R&D teams invest hundreds of millions optimizing drug formulations, stabilizing biologics, and engineering sophisticated combination products. Yet, a surprising number of next-generation drug delivery systems struggle to achieve commercial traction post-launch.
The root cause is surprisingly simple: R&D is engineered for regulatory clearance, not commercial adoption. While regulatory standards like IEC 62366 and regulations like the US FDA's QSR ensure a device is safe and effective for the intended users, uses and use environments, safety alone does not guarantee market success.
The Four Silent Vetoes in Combination Products
A drug delivery system must satisfy an entire ecosystem of stakeholders to be adopted and, thus, succeed on the market. Overlooking any single group creates a silent veto over your success:
Prescribers
If a novel delivery system adds complexity to patient consultations or alters established treatment algorithms, physicians default to legacy options.
Payers
Without clear economic and clinical workflow evidence generated during engineering development, reimbursement authorities won't support premium pricing models.
Care Teams & Nurses
Devices requiring extensive training or burdensome preparation steps face quiet resistance from frontline clinical staff.
Patients
If an auto-injector, wearable pump, or inhaler disrupts daily routines or causes anxiety, adherence drops and therapy switches occur.
Closing the Gap with Adoption-Driven R&D™
Fixing adoption post-launch is as costly, late, and ineffective as attempting to add usability after design freeze. Closing the adoption gap requires expanding traditional Human Factors Engineering into Adoption-Driven R&D™. By running structured, multi-stakeholder co-creation in parallel with standard ISO 13485 / IEC 62366 processes, combination product teams can:
Identify Market Whitespace
Validate prescriber, clinical, and patient
realities before locking design
inputs.
Engineer Ecosystem Fit
Deliver hardware, software, packaging, and labeling that pass design validation while eliminating operational friction.
Generate Sales & Payer Evidence
Convert human factors insights directly into commercial toolkits, clinical advocacy, and value dossiers.
Join the Discussion at Drug Delivery Summit 2026
Our Human Factors & Design Principal - Dr. Andreas Baier - will present the complete framework for integrating Adoption-Driven R&D™ into combination product pipelines at the Drug Delivery Summit 2026 (September 2–3, Frankfurt, Germany).
Want to see how Adoption-Driven R&D™ can be integrated into your existing design control workflow without extending your project timelines?
